DDX60L

Summary

DDX60L (DExD/H-box 60 like, HGNC:26429) is a protein-coding gene on chromosome 4q32.3, encoding Probable ATP-dependent RNA helicase DDX60-like (Q5H9U9).

This gene encodes a member of the DExD/H-box helicase family of proteins, a subset of the super family 2 helicases. Members of the DExD/H-box helicase family share a conserved functional core comprised of two RecA-like globular domains. These domains contain conserved motifs that mediate ATP binding, ATP hydrolysis, nucleic acid binding, and RNA unwinding. In addition to functions in RNA metabolism, members of this family are involved in anti-viral immunity and act as cytosolic sensors of viral nucleic acids. The protein encoded by this gene has been shown to inhibit hepatitis C virus replication in response to interferon stimulation in cell culture. Alternative splicing results in multiple transcript variants.

Source: NCBI Gene 91351 — RefSeq curated summary.

At a glance

• GWAS associations: 5
• Clinical variants (ClinVar): 307 total
• MANE Select transcript: NM_001012967

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:26429
Approved symbol	DDX60L
Name	DExD/H-box 60 like
Location	4q32.3
Locus type	gene with protein product
Status	Approved
Aliases	FLJ31033
Ensembl gene	ENSG00000181381
Ensembl biotype	protein_coding
OMIM	616725
Entrez	91351

Gene structure

Transcript identifiers

Ensembl transcripts: 22 — 14 protein_coding, 5 protein_coding_CDS_not_defined, 3 retained_intron

ENST00000503190, ENST00000504793, ENST00000505150, ENST00000505696, ENST00000505863, ENST00000505890, ENST00000510590, ENST00000511577, ENST00000512371, ENST00000512958, ENST00000513103, ENST00000513901, ENST00000514580, ENST00000514748, ENST00000515088, ENST00000682922, ENST00000854594, ENST00000854595, ENST00000854596, ENST00000929732, ENST00000943507, ENST00000943508

RefSeq mRNA: 7 — MANE Select: NM_001012967 NM_001012967, NM_001291510, NM_001345927, NM_001378069, NM_001378070, NM_001378071, NM_001378072

CCDS: CCDS47161

Canonical transcript exons

ENST00000682922 — 38 exons

Exon	Start	End
ENSE00001015931	168423608	168423774
ENSE00001015935	168422524	168422670
ENSE00001015942	168433010	168433115
ENSE00001015944	168427070	168427322
ENSE00001015948	168430478	168430638
ENSE00001015949	168432455	168432570
ENSE00001081478	168415657	168415799
ENSE00001081479	168403982	168404106
ENSE00001081483	168415408	168415517
ENSE00001081488	168405950	168406078
ENSE00001304567	168441337	168441492
ENSE00001479807	168448638	168448779
ENSE00001479809	168453124	168453282
ENSE00001479812	168456039	168456152
ENSE00001479814	168457892	168458008
ENSE00001479817	168461699	168462040
ENSE00001694037	168395959	168396124
ENSE00002441250	168379726	168379830
ENSE00002479661	168419302	168419397
ENSE00002486402	168384612	168384812
ENSE00002498664	168406602	168406706
ENSE00003463582	168361149	168361211
ENSE00003479266	168471747	168471936
ENSE00003523208	168378354	168378475
ENSE00003537591	168375377	168375524
ENSE00003541025	168416682	168416797
ENSE00003545481	168421760	168421909
ENSE00003563302	168379363	168379504
ENSE00003578112	168472696	168472809
ENSE00003585627	168356735	168358276
ENSE00003591051	168400826	168400978
ENSE00003594327	168472455	168472524
ENSE00003603500	168373666	168373808
ENSE00003608168	168420261	168420380
ENSE00003689338	168371612	168371763
ENSE00003916354	168391540	168391644
ENSE00003917895	168394465	168394617
ENSE00003920369	168480377	168480492

Expression profiles

Bgee: expression breadth ubiquitous, 229 present calls, max score 94.77.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 28.6555 / max 2415.4008, expressed in 1571 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
54775	28.5383	1558
54785	0.0607	24
54761	0.0565	29

Top tissues by expression

241 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	94.77	gold quality
leukocyte	CL:0000738	94.51	gold quality
jejunal mucosa	UBERON:0000399	93.99	gold quality
blood	UBERON:0000178	93.95	gold quality
visceral pleura	UBERON:0002401	92.27	gold quality
epithelial cell of pancreas	CL:0000083	91.60	gold quality
granulocyte	CL:0000094	91.26	gold quality
vermiform appendix	UBERON:0001154	89.40	gold quality
parietal pleura	UBERON:0002400	89.13	gold quality
placenta	UBERON:0001987	89.02	gold quality
trabecular bone tissue	UBERON:0002483	88.43	gold quality
bone marrow cell	CL:0002092	88.42	gold quality
spleen	UBERON:0002106	88.26	gold quality
decidua	UBERON:0002450	88.13	gold quality
calcaneal tendon	UBERON:0003701	87.85	gold quality
colonic mucosa	UBERON:0000317	87.76	gold quality
bone marrow	UBERON:0002371	87.75	gold quality
nasal cavity epithelium	UBERON:0005384	87.49	silver quality
mucosa of sigmoid colon	UBERON:0004993	87.40	gold quality
right lung	UBERON:0002167	87.34	gold quality
duodenum	UBERON:0002114	86.65	gold quality
sperm	CL:0000019	86.53	gold quality
thymus	UBERON:0002370	85.95	gold quality
tendon	UBERON:0000043	85.68	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	85.50	gold quality
subcutaneous adipose tissue	UBERON:0002190	85.25	gold quality
germinal epithelium of ovary	UBERON:0001304	85.20	gold quality
rectum	UBERON:0001052	85.19	gold quality
upper lobe of left lung	UBERON:0008952	85.04	gold quality
endometrium	UBERON:0001295	84.98	gold quality

Single-cell (SCXA)

Detected in 3 experiment(s), a significant marker in 3.

Experiment	Marker?	Max mean expression
E-MTAB-7037	yes	1182.92
E-MTAB-7052	yes	849.13
E-ANND-3	yes	10.06

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): NR1I2

miRNA regulators (miRDB)

58 targeting DDX60L, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-4682	100.00	68.89	1258
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4776-3P	100.00	68.73	1340
HSA-MIR-181A-5P	99.99	72.96	2995
HSA-MIR-181B-5P	99.99	72.97	2996
HSA-MIR-181C-5P	99.99	72.95	2996
HSA-MIR-181D-5P	99.99	73.04	2997
HSA-MIR-3662	99.99	73.82	5684
HSA-MIR-5696	99.98	72.36	4487
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-3658	99.96	73.87	4379
HSA-MIR-3529-3P	99.90	73.55	3045
HSA-MIR-6857-5P	99.87	65.32	985
HSA-MIR-579-3P	99.86	71.66	3628
HSA-MIR-664B-3P	99.84	71.65	3590
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-320A-3P	99.77	69.73	2107
HSA-MIR-320B	99.77	69.73	2107
HSA-MIR-320C	99.77	69.73	2107
HSA-MIR-320D	99.77	69.73	2107
HSA-MIR-4429	99.77	69.62	2111
HSA-MIR-6885-3P	99.75	70.36	3187
HSA-MIR-4729	99.69	72.18	4233
HSA-MIR-4527	99.66	67.43	714
HSA-MIR-587	99.64	70.86	2611
HSA-MIR-6503-5P	99.62	66.96	597
HSA-MIR-497-3P	99.61	69.71	1990
HSA-MIR-216A-5P	99.50	68.02	1288
HSA-MIR-365A-3P	99.43	70.02	836

Literature-anchored findings (GeneRIF, showing 2)

• DDX60L is an interferon-gamma stimulated gene product restricting Hepatitis C virus replication in cell culture. (PMID:26269178)
• Identification and functional analysis of novel oncogene DDX60L in pancreatic ductal adenocarcinoma. (PMID:34789165)

Cross-species orthologs

1 orthologs

Organism	Symbol	Gene ID
caenorhabditis_elegans		WBGENE00012896

Paralogs (8): MTREX (ENSG00000039123), POLQ (ENSG00000051341), ASCC3 (ENSG00000112249), DDX60 (ENSG00000137628), SNRNP200 (ENSG00000144028), HFM1 (ENSG00000162669), HELQ (ENSG00000163312), SKIC2 (ENSG00000204351)

Protein

Protein identifiers

Probable ATP-dependent RNA helicase DDX60-like — Q5H9U9 (reviewed: Q5H9U9)

Alternative names: DEAD box protein 60-like

All UniProt accessions (6): D6RB62, D6RBA2, D6RIU1, Q5H9U9, H0Y8H0, H0Y939

UniProt curated annotations — full annotation on UniProt →

Similarity. Belongs to the helicase family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q5H9U9-1	1	yes
Q5H9U9-2	2

RefSeq proteins (7): NP_001012985, NP_001278439, NP_001332856, NP_001364998, NP_001364999, NP_001365000, NP_001365001 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001650	Helicase_C-like	Domain
IPR011545	DEAD/DEAH_box_helicase_dom	Domain
IPR014001	Helicase_ATP-bd	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR052431	SKI2_subfamily_helicases	Family
IPR055124	PIN-like_DDX60	Domain
IPR059032	WHD_DDX60	Domain

Pfam: PF00270, PF00271, PF23002, PF26076, PF26167

Catalyzed reactions (Rhea), 1 shown:

• ATP + H2O = ADP + phosphate + H(+) (RHEA:13065)

UniProt features (23 total): sequence conflict 7, sequence variant 5, splice variant 3, domain 2, compositionally biased region 2, chain 1, region of interest 1, short sequence motif 1, binding site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q5H9U9-F1	79.77	0.28

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (1): 765–772

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 125 (showing top): GSE18804_SPLEEN_MACROPHAGE_VS_BRAIN_TUMORAL_MACROPHAGE_UP, GSE18804_BRAIN_VS_COLON_TUMORAL_MACROPHAGE_UP, chr4q32, TAKEDA_TARGETS_OF_NUP98_HOXA9_FUSION_10D_UP, DOUGLAS_BMI1_TARGETS_DN, GOBP_DEFENSE_RESPONSE_TO_VIRUS, DODD_NASOPHARYNGEAL_CARCINOMA_UP, GOBP_RESPONSE_TO_VIRUS, GOMF_SINGLE_STRANDED_RNA_BINDING, GOMF_HYDROLASE_ACTIVITY_ACTING_ON_ACID_ANHYDRIDES, GOMF_ATP_HYDROLYSIS_ACTIVITY, GOMF_ADENYL_NUCLEOTIDE_BINDING, GOMF_ISOMERASE_ACTIVITY, ZWANG_TRANSIENTLY_UP_BY_2ND_EGF_PULSE_ONLY, CSR_LATE_UP.V1_DN

GO Biological Process (1): defense response to virus (GO:0051607)

GO Molecular Function (10): RNA helicase activity (GO:0003724), double-stranded RNA binding (GO:0003725), single-stranded RNA binding (GO:0003727), ATP binding (GO:0005524), ATP hydrolysis activity (GO:0016887), nucleotide binding (GO:0000166), nucleic acid binding (GO:0003676), RNA binding (GO:0003723), helicase activity (GO:0004386), hydrolase activity (GO:0016787)

GO Cellular Component (1): cytoplasm (GO:0005737)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
RNA binding	2
ATP-dependent activity	2
defense response	1
response to virus	1
helicase activity	1
ATP-dependent activity, acting on RNA	1
catalytic activity, acting on RNA	1
adenyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
ribonucleoside triphosphate phosphatase activity	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
binding	1
nucleic acid binding	1
nucleic acid conformation isomerase activity	1
catalytic activity, acting on a nucleic acid	1
catalytic activity	1
intracellular anatomical structure	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1544 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
DDX60L	DDX49	Q9Y6V7	363
DDX60L	DDX50	Q9BQ39	344
DDX60L	IGHMBP2	P38935	337
DDX60L	RIGI	O95786	334
DDX60L	ZNF514	Q96K75	320
DDX60L	FBH1	Q8NFZ0	319
DDX60L	RUVBL2	Q9Y230	316
DDX60L	C4orf33	Q8N1A6	310
DDX60L	IFIT3	O14879	309
DDX60L	DQX1	Q8TE96	305
DDX60L	TTI1	O43156	304
DDX60L	IFI6	P09912	301
DDX60L	TMEM200C	A6NKL6	298
DDX60L	TNPO2	O14787	296
DDX60L	DDX20	Q9UHI6	295

IntAct

21 interactions, top by confidence:

A	B	Type	Score
EIF3I	EIF3F	psi-mi:“MI:0914”(association)	0.640
PTGES3	AIP	psi-mi:“MI:0914”(association)	0.530
HDGFL2	CDC7	psi-mi:“MI:0914”(association)	0.530
DDX60L	ATP5F1B	psi-mi:“MI:0915”(physical association)	0.400
DDX60L	H2BC21	psi-mi:“MI:0915”(physical association)	0.400
Vamp2	RTL8C	psi-mi:“MI:0914”(association)	0.350
ZSCAN26	TDG	psi-mi:“MI:0914”(association)	0.350
BMI1	MEIS3P1	psi-mi:“MI:0914”(association)	0.350
ZCCHC10	C1orf226	psi-mi:“MI:0914”(association)	0.350
C1orf174	POLRMT	psi-mi:“MI:0914”(association)	0.350
CAVIN1	GTPBP10	psi-mi:“MI:0914”(association)	0.350
HMGA1	GTPBP10	psi-mi:“MI:0914”(association)	0.350
IFNA14	AHCYL1	psi-mi:“MI:0914”(association)	0.350
MORF4L2	GTPBP10	psi-mi:“MI:0914”(association)	0.350
NPM3	GTPBP10	psi-mi:“MI:0914”(association)	0.350
RPS19	ZNF316	psi-mi:“MI:0914”(association)	0.350
RPS8	GTPBP10	psi-mi:“MI:0914”(association)	0.350
RRP8	POLRMT	psi-mi:“MI:0914”(association)	0.350
THAP11	XPC	psi-mi:“MI:0914”(association)	0.350
ZCCHC10	ARHGAP10	psi-mi:“MI:0914”(association)	0.350

BioGRID (32): DDX60L (Co-fractionation), DDX60L (Affinity Capture-MS), DDX60L (Affinity Capture-MS), DDX60L (Affinity Capture-MS), DDX60L (Affinity Capture-MS), DDX60L (Affinity Capture-MS), DDX60L (Affinity Capture-MS), DDX60L (Affinity Capture-MS), DDX60L (Affinity Capture-MS), DDX60L (Proximity Label-MS), DDX60L (Proximity Label-MS), DDX60L (Proximity Label-MS), DDX60L (Proximity Label-MS), DDX60L (Affinity Capture-MS), DDX60L (Affinity Capture-MS)

ESM2 similar proteins: A0A1B0GW35, A6QNM3, B0R034, B1ANS9, B9EK06, D2KC46, D3ZY60, F1MS15, F1P065, F1REV3, O00522, O15091, O75747, P10911, P58069, Q008S8, Q14449, Q14D04, Q15283, Q32NR9, Q45GW3, Q4R366, Q4R6T7, Q5H9U9, Q5K651, Q5PQS3, Q5XGX5, Q5XIZ9, Q5ZLD2, Q60862, Q63713, Q69Z37, Q6DCF6, Q6S5J6, Q6TNJ1, Q75PQ8, Q80W71, Q86VD1, Q86YR7, Q8C5W4

Diamond homologs: A0FLQ6, O08307, O34996, O51498, O52225, O75417, P19821, P30313, P35207, P46835, P52027, P52028, P56105, P74933, P80194, Q09475, Q54XN7, Q5H9U9, Q8CGS6, Q8IY21, Q9P7T8, Q9RAA9, Q9S1G2, Q9V0A9, A2PYH4, A2RUV5, A8MB76, B0R7Q2, B6DMK2, D3Z4R1, E1BNG3, E7F8F4, E9PZJ8, F1LNJ2, F1LPQ2, F1NTD6, F4JAA5, O48534, O59025, O60072

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

307 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	234
Likely benign	23
Benign	1

Top pathogenic / likely-pathogenic (0)

SpliceAI

6684 predictions. Top by Δscore:

Variant	Effect	Δscore
4:168371610:AC:A	donor_gain	1.0000
4:168371611:CC:C	donor_gain	1.0000
4:168373711:C:CT	acceptor_gain	1.0000
4:168375375:A:AC	donor_gain	1.0000
4:168375376:C:CA	donor_gain	1.0000
4:168375376:CTG:C	donor_gain	1.0000
4:168375376:CTGA:C	donor_gain	1.0000
4:168375522:CAC:C	acceptor_gain	1.0000
4:168375523:ACCT:A	acceptor_loss	1.0000
4:168375524:CCTA:C	acceptor_loss	1.0000
4:168375525:C:CG	acceptor_loss	1.0000
4:168375526:T:A	acceptor_loss	1.0000
4:168378374:A:C	donor_gain	1.0000
4:168390445:T:TA	donor_gain	1.0000
4:168391539:CCTGT:C	donor_gain	1.0000
4:168394463:AC:A	donor_gain	1.0000
4:168394464:CC:C	donor_gain	1.0000
4:168394618:C:CC	acceptor_gain	1.0000
4:168395954:CGTA:C	donor_gain	1.0000
4:168395957:A:AC	donor_gain	1.0000
4:168395958:C:CC	donor_gain	1.0000
4:168400980:T:C	acceptor_gain	1.0000
4:168403977:CTT:C	donor_loss	1.0000
4:168403978:TTA:T	donor_loss	1.0000
4:168403980:A:AC	donor_gain	1.0000
4:168403980:ACA:A	donor_loss	1.0000
4:168403981:C:CT	donor_gain	1.0000
4:168403981:CA:C	donor_gain	1.0000
4:168403981:CAA:C	donor_gain	1.0000
4:168403981:CAAA:C	donor_gain	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000094871 (4:168432086 T>C,G), RS1000108977 (4:168419628 A>G), RS1000115492 (4:168388006 A>C,G), RS1000124713 (4:168467861 G>A), RS1000181450 (4:168386694 A>T), RS10002007 (4:168478409 C>G,T), RS1000208015 (4:168438114 C>G), RS10002308 (4:168478672 C>A), RS1000245544 (4:168369282 T>C), RS1000252889 (4:168396222 G>A,T), RS1000267930 (4:168473864 T>C), RS10002730 (4:168399370 A>G,T), RS1000297208 (4:168450210 T>TA), RS1000303192 (4:168480043 C>T), RS1000333954 (4:168480384 G>A)

Disease associations

OMIM: gene MIM:616725 | disease phenotypes:

GenCC curated gene-disease

Mondo (2): prostate cancer (MONDO:0008315), breast ductal adenocarcinoma (MONDO:0005590)

Orphanet (1): Familial prostate cancer (Orphanet:1331)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

5 associations (top):

Study	Trait	p-value
GCST000767_2	Non-alcoholic fatty liver disease histology (AST)	6.000000e-07
GCST001762_300	Obesity-related traits	8.000000e-06
GCST005024_11	Pursuit maintenance gain	2.000000e-06
GCST008156_105	Hip circumference adjusted for BMI	2.000000e-06
GCST009391_501	Metabolite levels	1.000000e-06

EFO canonical traits (4, from GWAS)

EFO ID	Trait name
EFO:0003939	energy intake
EFO:0008433	pursuit maintenance gain measurement
EFO:0008039	BMI-adjusted hip circumference
EFO:0010525	propionic acid measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D018270	Carcinoma, Ductal, Breast	C04.557.470.200.025.232.500; C04.557.470.615.132.500; C04.588.180.390; C17.800.090.500.390
D011471	Prostatic Neoplasms	C04.588.945.440.770; C12.100.500.260.750; C12.100.500.565.625; C12.200.294.260.750; C12.200.294.565.625; C12.200.758.409.750; C12.900.619.750

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

30 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	affects cotreatment, increases abundance, increases expression	2
Tobacco Smoke Pollution	decreases expression	2
Aflatoxin B1	decreases methylation, increases methylation	2
aristolochic acid I	decreases expression	1
bisphenol A	decreases methylation	1
beta-lapachone	increases expression	1
arsenite	affects binding, decreases reaction	1
potassium chromate(VI)	decreases expression	1
nickel sulfate	decreases expression	1
di-n-butylphosphoric acid	affects expression	1
entinostat	increases expression	1
ICG 001	decreases expression	1
jinfukang	affects cotreatment, decreases expression	1
2,3,5-trichloro-6-phenyl-(1,4)benzoquinone	increases expression	1
Temozolomide	increases expression	1
Acetaminophen	decreases expression	1
Air Pollutants, Occupational	decreases expression	1
Arsenic	affects cotreatment, increases abundance, increases expression	1
Benzo(a)pyrene	decreases expression	1
Cisplatin	affects cotreatment, decreases expression	1
Doxorubicin	decreases expression	1
Estradiol	increases expression	1
Nickel	decreases expression	1
Ribonucleotides	affects binding	1
Silicon Dioxide	increases expression	1
Sodium Dodecyl Sulfate	decreases expression	1
Tretinoin	increases expression	1
Valproic Acid	decreases methylation	1
Zidovudine	affects cotreatment, increases expression	1
Okadaic Acid	increases expression	1

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B2MK	Abcam A-549 DDX60L KO	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00029224	PHASE4	COMPLETED	Treatment With Zoledronic Acid in Patients With Breast Cancer, Multiple Myeloma, and Prostate Cancer With Cancer Related Bone Lesions
NCT00035997	PHASE4	COMPLETED	Open-label Trial on the Effect of I.V. Zoledronic Acid 4 mg on Bone Density in Hormone Sensitive Prostate Cancer Patients With Bone Metastasis
NCT00063609	PHASE4	COMPLETED	The Effect of Zoledronic Acid on Bone Loss in Prostate Cancer Patients Undergoing Androgen Deprivation Therapy
NCT00103623	PHASE4	SUSPENDED	The Plenaxis® Experience Study
NCT00106392	PHASE4	COMPLETED	A Safety and Efficacy Study of Prograf in the Prevention of Erectile Dysfunction After Radical Prostatectomy
NCT00185029	PHASE4	UNKNOWN	MR-Lymphography and Lymph Node Staging in Prostate Cancer
NCT00199485	PHASE4	COMPLETED	Angelica Sinensis for the Treatment of Hot Flashes in Men Undergoing LHRH Therapy for Prostate Cancer
NCT00219219	PHASE4	COMPLETED	Zoledronic Acid in the Prevention of Skeletal-related Events in Hormone Refractory and Hormone-sensitive Prostate Cancer Patients With Bone Metastases
NCT00219271	PHASE4	COMPLETED	Effect Of Zoledronic Acid On Circulating And Bone Marrow-Residing Prostate Cancer Cells In Patients With Clinically Localized Prostate Cancer
NCT00237146	PHASE4	COMPLETED	Study to Evaluate Zoledronic Acid on Quality of Life and Skeletal-related Events as Adjuvant Treatment in Patients With Hormone-naïve Prostate Cancer and Bone Metastasis Who Have Undergone Orchiectomy
NCT00242554	PHASE4	COMPLETED	Open-label Phase IV Clinical Trial to Evaluate the Safety and Tolerability of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastases
NCT00280098	PHASE4	COMPLETED	Docetaxel in the Treatment of Hormone Refractory Prostate Cancer
NCT00293696	PHASE4	COMPLETED	Casodex/Zoladex Biomarkers in Localised Prostate Cancer
NCT00334139	PHASE4	COMPLETED	Effect of Zoledronic Acid on Bone Metabolism in Patients With Bone Metastasis and Prostate or Breast Cancer
NCT00375765	PHASE4	COMPLETED	Effects On Dihydrotestosterone Regulated Gene Expression In Benign Prostatic Hyperplasia Or Prostate Cancer
NCT00391690	PHASE4	COMPLETED	Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer
NCT00422708	PHASE4	COMPLETED	Local Anesthesia for Prostate Biopsy
NCT00526331	PHASE4	COMPLETED	Evaluation of Arterial Pressure Based Cardiac Output for Goal-Directed Perioperative Therapy
NCT00590213	PHASE4	COMPLETED	Compare the Value of Prophylactic Versus Therapeutic Breast Radiotherapy in CASODEX
NCT00629330	PHASE4	TERMINATED	Dissemination of Prostate Cancer Screening to PCP’s in African American Communities
NCT00771966	PHASE4	COMPLETED	Radical Prostatectomy and Perioperative Fluid Therapy
NCT00805701	PHASE4	COMPLETED	Study Assessing The Efficacy And Safety Of Avodart (Dutasteride) At Improving Urinary Symptoms In Men With Prostate Cancer Who Are Undergoing Seed Implantation
NCT00859027	PHASE4	COMPLETED	Effect Of Risedronate On Bone Mass In Older Men Receiving Neoadjuvant Therapy For Prostate Cancer
NCT00906269	PHASE4	UNKNOWN	Can Hyperbaric Oxygen Improve Erectile Function Following Surgery for Prostate Cancer
NCT00953277	PHASE4	COMPLETED	Study of Nerve Reconstruction Using AVANCE in Subjects Who Undergo Robotic Assisted Prostatectomy for Treatment of Prostate Cancer
NCT00982800	PHASE4	COMPLETED	Does Postoperative Gabapentin Reduce Pain, Opioid Consumption and Anxiety and Have a Positive Effect on Health Related Quality of Life After Radical Prostatectomy?
NCT01083199	PHASE4	COMPLETED	Global Performance Evaluation of the AMS CONTINUUM™ Device
NCT01136226	PHASE4	COMPLETED	Evaluate Recovery of Testosterone for Patients Using Eligard
NCT01161563	PHASE4	COMPLETED	Randomized Crossover Trial to Assess the Tolerability of Gonadotropin Releasing Hormone (GnRH) Analogue Administration
NCT01230905	PHASE4	COMPLETED	Study to Monitor the Effects of Androgen Suppression Treatment on the Heart
NCT01296672	PHASE4	COMPLETED	3 Month Finasteride Challenge Test Can Significantly Improve the Performance of Screening for Prostate Cancer
NCT01365143	PHASE4	TERMINATED	Prospective Randomized Trial Comparing Robotic Versus Open Radical Prostatectomy
NCT01379742	PHASE4	UNKNOWN	Comparison of Between ThinSeed™ and OncoSeed™ for Permanent Prostate Brachytherapy
NCT01486563	PHASE4	COMPLETED	Hydroxyethyl Starch and Renal Function After Radical Prostatectomy
NCT01511874	PHASE4	COMPLETED	Efficacy and Safety Study of ELIGARD 22.5mg With Prostate Cancer
NCT01512472	PHASE4	TERMINATED	Firmagon (Degarelix) Intermittent Therapy
NCT01547416	PHASE4	COMPLETED	The Effect of Combined General/Epidural Anesthesia Versus General Anesthesia on Diaphragmatic Function
NCT01571544	PHASE4	COMPLETED	The Use of Thermal Suits as Preventing Hypothermia During Surgery
NCT01581749	PHASE4	UNKNOWN	Evaluation of Truebeam for Low-Intermediate Risk Prostate Cancer
NCT01649635	PHASE4	COMPLETED	Study of Cabazitaxel Combined With Prednisone and Prophylaxis of Neutropenia Complications in the Treatment of Patients With Metastatic Castration-resistant Prostate Cancer